FDA accepts review of long-delayed Merck blood clot drug

July 24 - Merck & Co. on Wednesday said U.S. regulators had accepted its marketing application for the blood clot drug vorapaxar, aimed at preventing heart attacks and strokes in patients who have already had a heart attack but who have no history of stroke.

http://feedproxy.google.com/~r/reuters/healthNews/~3/TVFv_9SnsWQ/story01.htm

Source: Reuters: Health - July 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news